Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry - PubMed (original) (raw)
. 2012 Mar 1;30(7):729-34.
doi: 10.1200/JCO.2011.36.2574. Epub 2012 Jan 30.
Daniel Booser, Vicente Valero, James L Murray, Kimberly Koenig, Francisco J Esteva, Naoto T Ueno, Jie Zhang, Weiwei Shi, Yuan Qi, Junji Matsuoka, Elliana J Yang, Gabriel N Hortobagyi, Christos Hatzis, W Fraser Symmans, Lajos Pusztai
Affiliations
- PMID: 22291085
- DOI: 10.1200/JCO.2011.36.2574
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry
Takayuki Iwamoto et al. J Clin Oncol. 2012.
Abstract
Purpose: We examined borderline estrogen receptor (ER) -positive cancers, defined as having 1% to 10% positivity by immunohistochemistry (IHC), to determine whether they show the same global gene-expression pattern and high ESR1 mRNA expression as ER-positive cancers or if they are more similar to ER-negative cancers.
Patients and methods: ER status was determined by IHC in 465 primary breast cancers and with the Affymetrix U133A gene chip. We compared expressions of ESR1 mRNA and a 106 probe set ER-associated gene signature score between ER-negative (n = 183), 1% to 9% (n = 25), 10% (n = 6), and more than 10% (n = 251) ER-positive cancers. We also assessed the molecular class by using the PAM50 classifier and plotted survival by ER status.
Results: Among the 1% to 9%, 10%, and more than 10% ER IHC-positive patients, 24%, 67%, and 92% were also positive by ESR1 mRNA expression. The average ESR1 expression was significantly higher in the ≥ 10% ER-positive cohorts compared with the 1% to 9% or ER-negative cohort. The average ER gene signature scores were similar for the ER-negative and 1% to 9% IHC-positive patients and were significantly lower than in ≥ 10% ER-positive patients. Among the 1% to 9% ER-positive patients, 8% were luminal B and 48% were basal-like; among the 10% ER-positive patients, 50% were luminal. The overall survival rate of 1% to 9% ER-positive patients with cancer was between those of patients in the ≥ 10% ER-positive and ER-negative groups.
Conclusion: A minority of the 1% to 9% IHC ER-positive tumors show molecular features similar to those of ER-positive, potentially endocrine-sensitive tumors, whereas most show ER-negative, basal-like molecular characteristics. The safest clinical approach may be to use both adjuvant endocrine therapy and chemotherapy in this rare subset of patients.
Comment in
- Lost in translation? Estrogen receptor status and endocrine responsiveness in breast cancer.
Harbeck N, Rody A. Harbeck N, et al. J Clin Oncol. 2012 Mar 1;30(7):686-9. doi: 10.1200/JCO.2011.38.9619. Epub 2012 Jan 30. J Clin Oncol. 2012. PMID: 22291083 No abstract available. - Low-estrogen receptor-positive breast cancer: the impact of tissue sampling, choice of antibody, and molecular subtyping.
Rakha EA, Lee AH, Roberts J, Villena Salinas NM, Hodi Z, Ellis IO, Reis-Filho JS. Rakha EA, et al. J Clin Oncol. 2012 Aug 10;30(23):2929-30; author reply 2931. doi: 10.1200/JCO.2012.43.2831. Epub 2012 Jul 2. J Clin Oncol. 2012. PMID: 22753914 No abstract available.
Similar articles
- Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers.
Itoh M, Iwamoto T, Matsuoka J, Nogami T, Motoki T, Shien T, Taira N, Niikura N, Hayashi N, Ohtani S, Higaki K, Fujiwara T, Doihara H, Symmans WF, Pusztai L. Itoh M, et al. Breast Cancer Res Treat. 2014 Jan;143(2):403-9. doi: 10.1007/s10549-013-2763-z. Epub 2013 Dec 15. Breast Cancer Res Treat. 2014. PMID: 24337596 - Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors.
Muthukaruppan A, Lasham A, Woad KJ, Black MA, Blenkiron C, Miller LD, Harris G, McCarthy N, Findlay MP, Shelling AN, Print CG. Muthukaruppan A, et al. Clin Breast Cancer. 2017 Apr;17(2):139-153. doi: 10.1016/j.clbc.2016.09.001. Epub 2016 Sep 13. Clin Breast Cancer. 2017. PMID: 27756582 - Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart MJ, Dowsett M, Michiels S, Leyland-Jones B. Loi S, et al. JAMA Oncol. 2016 Aug 1;2(8):1040-7. doi: 10.1001/jamaoncol.2016.0339. JAMA Oncol. 2016. PMID: 27100299 - The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O, Seghers S, Sergoynne L, Van Gaver H, Papadimitriou K, Wouters K, Trinh XB, Huizing MT, Tjalma W. Najim O, et al. Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188315. doi: 10.1016/j.bbcan.2019.188315. Epub 2019 Oct 21. Biochim Biophys Acta Rev Cancer. 2019. PMID: 31647985 Review. - Clinical implication of low estrogen receptor (ER-low) expression in breast cancer.
Reinert T, Cascelli F, de Resende CAA, Gonçalves AC, Godo VSP, Barrios CH. Reinert T, et al. Front Endocrinol (Lausanne). 2022 Nov 24;13:1015388. doi: 10.3389/fendo.2022.1015388. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36506043 Free PMC article. Review.
Cited by
- Comparison of neoadjuvant chemotherapy response and prognosis among pegylated liposomal doxorubicin, epirubicin and pirarubicin in HR ⩽ 10%/HER2-negative breast cancer: an exploratory real-world multicentre cohort study.
Hong Y, Peng J, Chen Q, Zhou Q, Xu F, Yao J, Zou Q, Yuan L, Li L, Long Q, Liao L, Liu M, Liu X, Zhang D, Wang S, Yi W. Hong Y, et al. Ther Adv Med Oncol. 2024 Sep 23;16:17588359241279695. doi: 10.1177/17588359241279695. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39346118 Free PMC article. - Predicting invasive disease-free survival in ER-positive, HER2-negative early breast cancer using the PAM50 risk-of-recurrence score: a retrospective analysis using single-center long-term follow-up data of postmenopausal Japanese patients.
Higami A, Takada M, Kawaguchi-Sakita N, Kawashima M, Kawaguchi K, Yamaguchi A, Takeuchi Y, Yamada Y, Toi M. Higami A, et al. Int J Clin Oncol. 2024 Aug 23. doi: 10.1007/s10147-024-02604-1. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39177880 - MRI features of breast cancer immunophenotypes with a focus on luminal estrogen receptor low positive invasive carcinomas.
Tajima CC, Arruda FPSG, Mineli VC, Ferreira JM, Bettim BB, Osório CABT, Sonagli M, Bitencourt AGV. Tajima CC, et al. Sci Rep. 2024 Aug 20;14(1):19305. doi: 10.1038/s41598-024-69778-6. Sci Rep. 2024. PMID: 39164330 Free PMC article. - A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression.
Boman C, Liu X, Eriksson Bergman L, Sun W, Tranchell C, Toli MA, Acs B, Bergh J, Foukakis T, Matikas A. Boman C, et al. Br J Cancer. 2024 Sep;131(4):718-728. doi: 10.1038/s41416-024-02777-6. Epub 2024 Jun 28. Br J Cancer. 2024. PMID: 38942987 Free PMC article. - Real-world overall survival and characteristics of patients with ER-zero and ER-low HER2-negative breast cancer treated as triple-negative breast cancer: a Swedish population-based cohort study.
Acs B, Hartman J, Sönmez D, Lindman H, Johansson ALV, Fredriksson I. Acs B, et al. Lancet Reg Health Eur. 2024 Mar 19;40:100886. doi: 10.1016/j.lanepe.2024.100886. eCollection 2024 May. Lancet Reg Health Eur. 2024. PMID: 38745990 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous